Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KYMR NASDAQ:MLYS NASDAQ:NUVL NASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$114.16-4.3%$89.15$36.65▼$130.05$9.81B1.951.25 million shs787,990 shsMLYSMineralys Therapeutics$30.40-0.2%$27.21$12.59▼$47.65$2.51B0.661.63 million shs995,377 shsNUVLNuvalent$123.80+0.0%$110.79$71.13▼$123.85$9.78B1.142.67 million shs1.16 million shsPRAXPraxis Precision Medicines$332.99+2.8%$312.49$37.19▼$366.52$9.03B2.74581,758 shs559,324 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics+3.90%+3.99%+60.85%+36.85%+172.18%MLYSMineralys Therapeutics+4.60%+12.90%+28.58%+9.73%+125.13%NUVLNuvalent+0.04%+0.22%+36.09%+17.83%+58.82%PRAXPraxis Precision Medicines+3.33%-3.24%+27.54%+1.16%+593.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$114.16-4.3%$89.15$36.65▼$130.05$9.81B1.951.25 million shs787,990 shsMLYSMineralys Therapeutics$30.40-0.2%$27.21$12.59▼$47.65$2.51B0.661.63 million shs995,377 shsNUVLNuvalent$123.80+0.0%$110.79$71.13▼$123.85$9.78B1.142.67 million shs1.16 million shsPRAXPraxis Precision Medicines$332.99+2.8%$312.49$37.19▼$366.52$9.03B2.74581,758 shs559,324 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics+3.90%+3.99%+60.85%+36.85%+172.18%MLYSMineralys Therapeutics+4.60%+12.90%+28.58%+9.73%+125.13%NUVLNuvalent+0.04%+0.22%+36.09%+17.83%+58.82%PRAXPraxis Precision Medicines+3.33%-3.24%+27.54%+1.16%+593.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKYMRKymera Therapeutics 2.96Moderate Buy$121.416.35% UpsideMLYSMineralys Therapeutics 2.63Moderate Buy$49.3362.28% UpsideNUVLNuvalent 2.15Hold$127.733.17% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$569.6371.07% UpsideCurrent Analyst Ratings BreakdownLatest MLYS, KYMR, NUVL, and PRAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026KYMRKymera Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$110.00 ➝ $125.006/29/2026KYMRKymera Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$117.00 ➝ $155.006/29/2026KYMRKymera Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$116.00 ➝ $136.006/29/2026PRAXPraxis Precision Medicines Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$537.00 ➝ $575.006/26/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$106.00 ➝ $129.006/25/2026KYMRKymera Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$134.006/24/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$172.00 ➝ $124.006/17/2026PRAXPraxis Precision Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$449.006/17/2026PRAXPraxis Precision Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy6/10/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/10/2026NUVLNuvalent GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$151.00 ➝ $124.00(Data available from 7/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKYMRKymera Therapeutics$39.21M239.50N/AN/A$19.42 per share5.88MLYSMineralys TherapeuticsN/AN/AN/AN/A$8.17 per shareN/ANUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/APRAXPraxis Precision Medicines$8.55M1,085.82N/AN/A$34.85 per share9.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)MLYSMineralys Therapeutics-$154.65M-$2.05N/AN/AN/AN/A-27.92%-26.98%8/11/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)Latest MLYS, KYMR, NUVL, and PRAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/3/2026Q2 2026PRAXPraxis Precision Medicines-$3.6683N/AN/AN/A$1.25 millionN/A5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/6/2026Q1 2026MLYSMineralys Therapeutics-$0.51-$0.47+$0.04-$0.47N/AN/A4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKYMRKymera TherapeuticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKYMRKymera TherapeuticsN/A10.8110.81MLYSMineralys TherapeuticsN/A44.3344.33NUVLNuvalentN/A16.1416.14PRAXPraxis Precision MedicinesN/A15.8815.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKYMRKymera TherapeuticsN/AMLYSMineralys Therapeutics84.46%NUVLNuvalent97.26%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipKYMRKymera Therapeutics15.98%MLYSMineralys Therapeutics18.94%NUVLNuvalent5.02%PRAXPraxis Precision Medicines3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableMLYSMineralys Therapeutics2882.50 million66.87 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.04 millionOptionableMLYS, KYMR, NUVL, and PRAX HeadlinesRecent News About These CompaniesPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 8 at 3:36 AM | americanbankingnews.comPraxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential TremorJuly 7 at 8:00 AM | globenewswire.comS&P 500 Futures Climb in Premarket Trading; Praxis Precision Meds, IREN LeadJuly 6 at 12:04 PM | barrons.comAnalysts Are Bullish on These Healthcare Stocks: Praxis Precision Medicines (PRAX), Aurora Cannabis (ACB)July 3, 2026 | theglobeandmail.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.comJefferies Keeps Their Buy Rating on Praxis Precision Medicines (PRAX)July 2, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Outlook Therapeutics (OTLK), Praxis Precision Medicines (PRAX) and Merck & Company (MRK)July 1, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Boston Scientific (BSX)July 1, 2026 | theglobeandmail.comPraxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic ...June 30, 2026 | finanznachrichten.deStocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision MedicinesJune 29, 2026 | marketwatch.comPraxis Precision Medicines Says FDA Extends Review of Relutrigine ApplicationJune 29, 2026 | marketwatch.comPraxis Precision Medicines Announces FDA Extends Review of Relutrigine NDA to December 27, 2026June 29, 2026 | quiverquant.comQPraxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic EncephalopathiesJune 29, 2026 | globenewswire.comJill Desimone Sells 11,600 Shares of Praxis Precision Medicines (NASDAQ:PRAX) StockJune 28, 2026 | americanbankingnews.comInsider Selling: Praxis Precision Medicines (NASDAQ:PRAX) Director Sells $3,611,312.00 in StockJune 27, 2026 | insidertrades.comPraxis Precision Medicines (PRAX): Best Upside Stocks to Buy According to Hedge FundsJune 24, 2026 | insidermonkey.comPraxis 'Strong Buy': PDUFA In Early 2027 For Ulixacaltamide And BTD ElsunersenJune 23, 2026 | seekingalpha.comPraxis Wins FDA Breakthrough Status for Elsunersen Epilepsy DrugJune 22, 2026 | tipranks.comPraxis Shares Rise on FDA Breakthrough Therapy Designation for ElsunersenJune 22, 2026 | marketwatch.comPraxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic ...June 22, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 2026Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionBy Jeffrey Neal Johnson | June 11, 2026MLYS, KYMR, NUVL, and PRAX Company DescriptionsKymera Therapeutics NASDAQ:KYMR$114.16 -5.08 (-4.26%) Closing price 04:00 PM EasternExtended Trading$116.44 +2.28 (+2.00%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Mineralys Therapeutics NASDAQ:MLYS$30.40 -0.06 (-0.20%) Closing price 04:00 PM EasternExtended Trading$31.00 +0.60 (+1.96%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Nuvalent NASDAQ:NUVL$123.80 +0.03 (+0.02%) Closing price 04:00 PM EasternExtended Trading$123.73 -0.07 (-0.06%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Praxis Precision Medicines NASDAQ:PRAX$332.99 +9.04 (+2.79%) Closing price 04:00 PM EasternExtended Trading$336.65 +3.66 (+1.10%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Exxon Could Be the Market's Next Big Comeback Stock Why Penguin Solutions May Be the Smartest AI Infrastructure Stock The Market Just Got Shaken—These 3 ETFs May Come Out Stronger Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns A Market Panic Just Discounted the AI Highway's Tollbooth Vertex’s Crinetics Deal Balances Growth with Integration Risk Apple and Broadcom Forge a Decade-Long Silicon Fortress These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
